InspireMD Inc. (NASDAQ:NSPR) Q3 2023 Results Earnings Conference Call November 6, 2023 8:30 AM ET
Company Participants
Charles Padala - Investor Relations, LifeSci Advisors
Marvin Slosman - President, CEO and Director
Craig Shore - Chief Financial Officer
Conference Call Participants
Adam Maeder - Piper Sandler
Benjamin Haynor - Alliance Global Partners
Operator
Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note that this conference is being recorded.
I will now turn the conference over to Chuck Padala with LifeSci Advisors. Thank you. You may begin.
Charles Padala
Thank you, operator. And good morning, everyone. Thank you for joining us for the InspireMD third quarter 2023 financial results and corporate update conference call.
Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer, and Craig Shore, Chief Financial Officer.
During this call, management will be making forward-looking statements, not historical facts, which are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.
These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. For more information about these risks, please refer to the risk factors described in InspireMD's most recently filed periodic reports on Form 10-K and Form 10-Q or on any updates in our current reports on Form 8-K filed with the US Securities and Exchange Commission and InspireMD's press release that accompanies this call, particularly the cautionary statements made in it.
The call contains time-sensitive information that is accurate only as of today, November 6, 2023. Except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call.
It's now my pleasure to turn the call over to Marvin Slosman, CEO. Please go ahead, Marvin.
Marvin Slosman
Thank you, Chuck. And thanks to everyone for joining the call this morning. The third quarter proved to be a transformational time for our company with several milestones, further validating our strategy and mission to transform the carotid revascularization market with a superior next generation stent implant, along with our focus on the broadest range of tools, providing both patients and physicians optimal procedural solutions.
Execution against internal objectives remains our focus, but I would like to start today with a brief mention of the recent national coverage decision by CMS, enabling a monumental shift by expanding reimbursement for carotid artery stenting or CAS procedures to include those standard surgical risk and asymptomatic patients, neither of which were previously covered. We will get into those details shortly.